Annovis Bio Strengthens Alzheimer's Research Team with Key Biostatistics Appointment

Annovis Bio Inc. (NYSE: ANVS) has appointed Hui Liu as its new Director of Biostatistics, bolstering its scientific capabilities in neurodegenerative disease research. With over 19 years of experience in clinical trial design, analysis, and regulatory submission support, Liu is positioned to significantly contribute to the company's ongoing Alzheimer's disease research.

Liu's expertise is particularly critical as Annovis Bio advances its Phase 3 clinical trial for Alzheimer's disease. Her extensive background in multiple therapeutic areas will help reinforce the scientific integrity of the company's data and enhance its regulatory strategies for developing transformative therapies.

The appointment underscores Annovis Bio's commitment to developing innovative treatments targeting neurodegenerative disorders. By leveraging Liu's significant experience, the company aims to improve its approach to clinical research and potentially accelerate the development of therapies that could restore brain function and improve patient quality of life.

As neurodegenerative diseases continue to pose significant global health challenges, strategic scientific appointments like Liu's represent important steps in advancing potential treatment options. Her expertise will be crucial in analyzing complex clinical trial data and supporting the company's goal of developing therapies for conditions like Alzheimer's and Parkinson's.